Compare NWE & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWE | IRTC |
|---|---|---|
| Founded | 1923 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.9B |
| IPO Year | 2023 | 2016 |
| Metric | NWE | IRTC |
|---|---|---|
| Price | $70.20 | $114.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $66.50 | ★ $197.92 |
| AVG Volume (30 Days) | 313.8K | ★ 462.5K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $1,610,559,000.00 | $747,138,000.00 |
| Revenue This Year | $8.84 | $19.60 |
| Revenue Next Year | $5.31 | $15.94 |
| P/E Ratio | $69.75 | ★ N/A |
| Revenue Growth | 6.38 | ★ 26.24 |
| 52 Week Low | $50.46 | $112.31 |
| 52 Week High | $75.18 | $210.01 |
| Indicator | NWE | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 45.30 | 42.63 |
| Support Level | $69.38 | $112.65 |
| Resistance Level | $71.47 | $127.50 |
| Average True Range (ATR) | 1.66 | 6.43 |
| MACD | -0.29 | -0.72 |
| Stochastic Oscillator | 15.46 | 12.08 |
NorthWestern Energy Group Inc provides electricity and natural gas services in the Upper Midwest and Northwest of the U.S. in the states of Montana, South Dakota, Nebraska, and Yellowstone National Park. The company's primary segments include Electric, which includes the generation, purchase, transmission, and distribution of electricity, and Natural Gas, which includes the production, purchase, transmission, storage, and distribution of natural gas. It uses thermal, wind, hydro, or renewable energy in varying quantities, depending on the location of the facilities, to generate power. The company derives the majority of its revenue from the Electric segment.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.